Hypromellose (HPMC) capsules were originally formulated with a secondary gelling agent. This agent can delay dissolution in some circumstances and lead to unwanted issues during product development. This whitepaper discusses the rationale for developing Capsugel’s Vcaps® Plus capsules without a gelling agent. It describes how these capsules – now in use at many major pharmaceutical companies to encapsulate their existing over-the-counter [OTC] products and New Chemical Entities [NCEs] – can optimize product performance and improve product stability, as well as reduce development timelines.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest CHI content
Latest briefing from the Knowledge Center